SWOT Analysis

Strength: The muscle spasticity market benefits from the availability of advanced treatment options like botulinum toxin injections and antispasticity medication.
Weakness: High treatment costs associated with intrathecal baclofen therapy and surgical interventions can limit their adoption rate.
Opportunity: Development of novel drug formulations, gene therapies, and stem cell-based treatments can present new growth opportunities.
Threats: Stringent regulations for approval of new drugs and high failure rates during clinical trials are major challenges.

Key Takeaways

The Global Muscle Spasticity Market Size was valued at US$ 4,167.6 million in 2023 and is expected to witness high growth, exhibiting a CAGR of 8.9% over the forecast period. The rising incidence of neurological disorders globally is a key driver for market growth.

Regional analysis
North America dominated the global market in 2023 and is expected to remain the fastest growing region during the forecast period. This can be attributed to the growing multiple sclerosis patient pool in the US and Canada and high adoption of advanced treatment approaches. Asia Pacific is anticipated to witness the highest CAGR owing to increasing healthcare expenditures and awareness regarding muscle spasticity management in China and India.

Key players
Key players operating in the muscle spasticity market are Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc. The market is competitive in nature with these major players adopting strategies like partnerships, collaborations and new product launches.

Read More  -  https://www.articlequarter.com/market-the-emerging-prospects-of-muscle-spasticity-therapeutics/